Compare iShares MSCI Hong Kong ETF (EWH) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI Hong Kong ETF trades at $22.47, while Merck & Co., Inc. trades at $131.69 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares MSCI Hong Kong ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | MRK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $131.84 |
52-Week Low | $20.66 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, a US-listed stock tracking Hong Kong equities, trades at $22.465, down 1.47% over 24 hours. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators are neutral. The stock faces resistance at $23 and support at $22. Recent news highlights the Hang Seng Index's rebound, driven by technology sector gains, with EWH positioned to benefit from this momentum.
The outlook for EWH hinges on Hong Kong market performance, with potential upside from continued tech recovery and Asian market stability. Risks include regional volatility and macroeconomic pressures. Analysts show mixed sentiment, balancing technical bearishness with fundamental opportunities in the rebounding index.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
